BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-409-5444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees20
Next Earnings Date10/30/2019 (Estimated)
OptionableNot Optionable
BioSig Technologies (NASDAQ:BSGM) Frequently Asked Questions
What is BioSig Technologies' stock symbol?
BioSig Technologies trades on the NASDAQ under the ticker symbol "BSGM."
How were BioSig Technologies' earnings last quarter?
BioSig Technologies Inc (NASDAQ:BSGM) released its quarterly earnings results on Wednesday, July, 31st. The company reported ($0.38) earnings per share for the quarter. View BioSig Technologies' Earnings History.
When is BioSig Technologies' next earnings date?
What price target have analysts set for BSGM?
2 Wall Street analysts have issued twelve-month price targets for BioSig Technologies' stock. Their forecasts range from $11.00 to $14.00. On average, they expect BioSig Technologies' stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 51.3% from the stock's current price. View Analyst Price Targets for BioSig Technologies.
What is the consensus analysts' recommendation for BioSig Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSig Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioSig Technologies.
Has BioSig Technologies been receiving favorable news coverage?
Press coverage about BSGM stock has trended somewhat negative on Monday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioSig Technologies earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for BioSig Technologies.
Are investors shorting BioSig Technologies?
BioSig Technologies saw a increase in short interest in August. As of August 31st, there was short interest totalling 1,840,800 shares, an increase of 33.2% from the July 31st total of 1,381,900 shares. Based on an average daily volume of 225,700 shares, the short-interest ratio is presently 8.2 days. Approximately 11.6% of the shares of the stock are short sold. View BioSig Technologies' Current Options Chain.
Who are some of BioSig Technologies' key competitors?
Some companies that are related to BioSig Technologies include AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), BioLife Solutions (BLFS), Viewray (VRAY), Zynex (ZYXI), Semler Scientific (SMLR), Stereotaxis (STXS), Rockwell Medical (RMTI), electroCore (ECOR), Fonar (FONR), Edap Tms (EDAP), Second Sight Medical Products (EYES), Soleno Therapeutics (SLNO) and Helius Medical Technologies (HSDT).
What other stocks do shareholders of BioSig Technologies own?
Who are BioSig Technologies' key executives?
BioSig Technologies' management team includes the folowing people:
- Mr. Kenneth L. Londoner M.B.A., MBA, Founder, CEO & Exec. Chairman (Age 51)
- Mr. Steven Chaussy, Chief Financial Officer (Age 65)
- Ms. Lora Mikolaitis, VP of Admin. (Age 46)
- Mrs. Tiffini Wittwer, Chief Regulatory & Compliance Officer
- Mr. John Kowalski, VP of Sales
Who are BioSig Technologies' major shareholders?
BioSig Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.73%), Vanguard Group Inc. (2.69%), Zeke Capital Advisors LLC (0.90%), Northern Trust Corp (0.31%), Charles Schwab Investment Management Inc. (0.19%) and Bank of New York Mellon Corp (0.16%). Company insiders that own BioSig Technologies stock include Andrew Lawrence Filler, Donald E Foley, Joseph Rafferty, Kenneth L Londoner, Patrick Joseph Gallagher and Steve Chaussy. View Institutional Ownership Trends for BioSig Technologies.
Which major investors are selling BioSig Technologies stock?
Which major investors are buying BioSig Technologies stock?
BSGM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, Morgan Stanley, NEXT Financial Group Inc and Ladenburg Thalmann Financial Services Inc.. Company insiders that have bought BioSig Technologies stock in the last two years include Andrew Lawrence Filler, Donald E Foley, Joseph Rafferty, Kenneth L Londoner, Patrick Joseph Gallagher and Steve Chaussy. View Insider Buying and Selling for BioSig Technologies.
How do I buy shares of BioSig Technologies?
Shares of BSGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioSig Technologies' stock price today?
One share of BSGM stock can currently be purchased for approximately $8.26.
How big of a company is BioSig Technologies?
What is BioSig Technologies' official website?
How can I contact BioSig Technologies?
BioSig Technologies' mailing address is 54 WILTON ROAD, WESTPORT CT, 06880. The company can be reached via phone at 203-409-5444 or via email at [email protected]
MarketBeat Community Rating for BioSig Technologies (NASDAQ BSGM)
MarketBeat's community ratings are surveys of what our community members think about BioSig Technologies and other stocks. Vote "Outperform" if you believe BSGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
